Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Change in Accured Expenses for 4 consecutive years, with $636970.0 as the latest value for Q4 2020.

  • Quarterly Change in Accured Expenses rose 109.37% to $636970.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $447598.0 through Dec 2020, up 83.79% year-over-year, with the annual reading at $388218.0 for FY2025, 23.4% down from the prior year.
  • Change in Accured Expenses hit $636970.0 in Q4 2020 for Monopar Therapeutics, up from -$21418.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $636970.0 in Q4 2020 to a low of -$331106.0 in Q1 2020.
  • Historically, Change in Accured Expenses has averaged $64135.8 across 4 years, with a median of $43201.5 in 2017.
  • Biggest YoY gain for Change in Accured Expenses was 889.15% in 2019; the steepest drop was 1050.57% in 2019.
  • Year by year, Change in Accured Expenses stood at -$26070.0 in 2017, then surged by 436.24% to $87658.0 in 2018, then surged by 247.06% to $304229.0 in 2019, then soared by 109.37% to $636970.0 in 2020.
  • Business Quant data shows Change in Accured Expenses for MNPR at $636970.0 in Q4 2020, -$21418.0 in Q3 2020, and $163152.0 in Q2 2020.